File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quantification of Plasma β-Catenin mRNA in Colorectal Cancer and Adenoma Patients

TitleQuantification of Plasma β-Catenin mRNA in Colorectal Cancer and Adenoma Patients
Authors
Issue Date2004
Citation
Clinical Cancer Research, 2004, v. 10 n. 5, p. 1613-1617 How to Cite?
AbstractPurpose: Colorectal cancer is an important cause of cancer deaths. Here, we focused our investigation on the β-catenin gene which is implicated in colorectal carcinogenesis and tested whether β-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenoma patients using quantitative reverse transcriptase-PCR. Experimental Design: Plasma β-catenin mRNA was measured from 58 colorectal carcinoma patients, 49 colorectal adenoma patients, and 43 apparently normal subjects using intron-spanning primers and Taqman probes. Five clinicopathological parameters were studied and correlated with plasma β-catenin mRNA concentration. Additionally, 19 colorectal carcinoma patients after tumor removal were also recruited for plasma β-catenin mRNA measurement to further demonstrate the clinical usefulness of this test. Results: β-catenin mRNA was detected with median concentrations of 8737 (range: 1480-933,100), 1218 (range: 541-2,254) and 291 (range: 0-1,366) copies/mi plasma in colorectal carcinoma, colorectal adenoma, and apparently normal subjects, respectively. Statistical analysis demonstrated that plasma β-catenin mRNA concentration was correlated to tumor stage but not sex, age, lymph node status, and degree in differentiation. Moreover, plasma β-catenin mRNA concentration decreased significantly after tumor removal in 16 of 19 (84%) colorectal carcinoma patients. Conclusions: We conclude that plasma β-catenin mRNA may potentially serve as a marker for colorectal cancer.
Persistent Identifierhttp://hdl.handle.net/10722/172871
ISSN
2023 Impact Factor: 10.0
2023 SCImago Journal Rankings: 4.623
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, SCCen_US
dc.contributor.authorLo, SFEen_US
dc.contributor.authorCheung, MTen_US
dc.contributor.authorNg, KOEen_US
dc.contributor.authorTse, CTen_US
dc.contributor.authorLai, BSPen_US
dc.contributor.authorLee, KCen_US
dc.contributor.authorLo, YMDen_US
dc.date.accessioned2012-10-30T06:25:26Z-
dc.date.available2012-10-30T06:25:26Z-
dc.date.issued2004en_US
dc.identifier.citationClinical Cancer Research, 2004, v. 10 n. 5, p. 1613-1617en_US
dc.identifier.issn1078-0432en_US
dc.identifier.urihttp://hdl.handle.net/10722/172871-
dc.description.abstractPurpose: Colorectal cancer is an important cause of cancer deaths. Here, we focused our investigation on the β-catenin gene which is implicated in colorectal carcinogenesis and tested whether β-catenin mRNA is detectable in the plasma of colorectal carcinoma and adenoma patients using quantitative reverse transcriptase-PCR. Experimental Design: Plasma β-catenin mRNA was measured from 58 colorectal carcinoma patients, 49 colorectal adenoma patients, and 43 apparently normal subjects using intron-spanning primers and Taqman probes. Five clinicopathological parameters were studied and correlated with plasma β-catenin mRNA concentration. Additionally, 19 colorectal carcinoma patients after tumor removal were also recruited for plasma β-catenin mRNA measurement to further demonstrate the clinical usefulness of this test. Results: β-catenin mRNA was detected with median concentrations of 8737 (range: 1480-933,100), 1218 (range: 541-2,254) and 291 (range: 0-1,366) copies/mi plasma in colorectal carcinoma, colorectal adenoma, and apparently normal subjects, respectively. Statistical analysis demonstrated that plasma β-catenin mRNA concentration was correlated to tumor stage but not sex, age, lymph node status, and degree in differentiation. Moreover, plasma β-catenin mRNA concentration decreased significantly after tumor removal in 16 of 19 (84%) colorectal carcinoma patients. Conclusions: We conclude that plasma β-catenin mRNA may potentially serve as a marker for colorectal cancer.en_US
dc.languageengen_US
dc.relation.ispartofClinical Cancer Researchen_US
dc.subject.meshAdenoma - Blood - Geneticsen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshColorectal Neoplasms - Blood - Geneticsen_US
dc.subject.meshCytoskeletal Proteins - Blood - Geneticsen_US
dc.subject.meshDna Primersen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMolecular Sequence Dataen_US
dc.subject.meshRna, Messenger - Blood - Geneticsen_US
dc.subject.meshReference Valuesen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshTrans-Activators - Blood - Geneticsen_US
dc.subject.meshBeta Cateninen_US
dc.titleQuantification of Plasma β-Catenin mRNA in Colorectal Cancer and Adenoma Patientsen_US
dc.typeArticleen_US
dc.identifier.emailNg, KOE: ngko@hku.hken_US
dc.identifier.authorityNg, KOE=rp01364en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1158/1078-0432.CCR-1168-3en_US
dc.identifier.pmid15014011-
dc.identifier.scopuseid_2-s2.0-1842585925en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1842585925&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume10en_US
dc.identifier.issue5en_US
dc.identifier.spage1613en_US
dc.identifier.epage1617en_US
dc.identifier.isiWOS:000220089100010-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, SCC=26039647800en_US
dc.identifier.scopusauthoridLo, SFE=23103463100en_US
dc.identifier.scopusauthoridCheung, MT=7201897489en_US
dc.identifier.scopusauthoridNg, KOE=21135553700en_US
dc.identifier.scopusauthoridTse, CT=36958765600en_US
dc.identifier.scopusauthoridLai, BSP=36724448700en_US
dc.identifier.scopusauthoridLee, KC=8880249900en_US
dc.identifier.scopusauthoridLo, YMD=7401935391en_US
dc.identifier.issnl1078-0432-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats